Ever since the discovery of small non-coding RNAs, microRNAs have been identified to play a critical role in development and function of pancreatic insulin-producing beta cells. Research carried out until now demonstrates that microRNAs can specifically target key pancreatic transcription factors and signalling molecules. This in turn may influence changes in insulin production and secretion. microRNAs are also identified in insulin target organs that are altered as a result of hyperglycemia and insulin resistance. Recent studies demonstrate that microRNAs are not only confined to cells but are also detected in biological fluids including serum, plasma and urine. These data indicate that miRNAs may be looked upon having a dual role, as biomarkers and as regulators of disease. We review the existing literature in understanding the role of microRNAs in development, function and death of pancreatic beta cells as well as in the development of metabolic disease. We discuss the possible mechanisms that contribute to identifying the role of microRNAs as sensitive and efficient biomarkers to predict the progression of diabetes. Understanding tissue-specific microRNA signatures and their role as a cause or effect of diabetes would provide more information on progression of this disease.
Introduction to microRnAs (miRnA)
Since the discovery of the first non coding RnA by Lee et al in 1993 [1] , 21,643 mature miRnAs in 168 species have been described (miRBase release 18, november 2011) [2] . These represent approximately 1% of the genome in different species and, in humans, target approximately 30% of protein coding genes [3] . microRnAs are small non-coding RnAs of around [18] [19] [20] [21] [22] nucleotides in length, which are highly conserved across species [4] . mature miRnAs are processed in 2 stages from primarymiRnA transcripts (pri-miRnAs), which are the longer precursors to the mature miRnA molecules [5] . The first stage occurs in the nucleus where pri-miRnAs are cleaved by the Rnase III enzyme Drosha to generate 70 to 100 nucleotide long hairpin miRnA precursors (pre-miRnA) [6] . Pre-miRnA sequences possess a 2 nucleotide overhang at the 3' end. Following transport of premiRnA into the cytoplasm [7] , the Rnase III enzyme Dicer cleaves sequences to generate miRnA duplexes ~ 22 nucleotides in length [8] . One strand of these duplexes is then selected for incorporation into a ribonucleoprotein complex called the RnAinduced silencing complex (RISc) and functions as a mature miRnA. Proteins of the Argonaute family are key components of RISc, with Argonaute 2 (Ago2) shown to play a critical role in miRnA-mediated mRnA silencing [9, 10] . mature miRnA guides the RISc to complementary mRnA sequences, usually in the 3' untranslated region (3'-UTR). Partial complementarity between the miRnA and mRnA leads to inhibition of translation whilst perfect complementarity results in degradation of the target mRnA [3, 11, 12] . (Summarized in Figure 1 )
It has been estimated that each miRnA may be regulating around 200 transcripts [13] . miRnAs play vital roles in all biological processes including proliferation, differentiation, cell growth, cell death and stress resistance (reviewed by [3, 12] ).
Whilst majority of miRnAs are found intracellularly, a number of miRnAs have also been detected outside of cells; in body fluids including serum / plasma [14] [15] [16] , urine [17, 18] , faeces [19, 20] , saliva [21, 22] and breast milk [23] . It is now widely accepted that miRnAs in the circulation can act as biomarkers of certain diseases, particularly cancer. This review will examine the role of microRnAs in pancreas biology, in insulin target tissues as well as in prediction of diabetes (Table 1) .
microRnAs in pancreas biology
It has been well demonstrated that miRnAs are a requirement for life. In the complete absence of the miRnA processing enzyme Dicer1, mice fail to complete normal embryonic development [24] . Dicer-1 expression levels at 20% of normal were shown to be sufficient for normal development [25] and survival of [44] [45] [46] . All these articles confirm the importance of miRnAs in pancreas biology. These islet-specific miRnAs are believed to fine-tune many of the physiological and pathological events in pancreatic beta cells. Islet specific miRnAs (including miR-375, miR-9, miR-7, miR-30 family, miR-338-3p, miR-29a/b/c, miR-21, miR-124a) have been described in depth in recent reviews and will not be covered here [47] [48] [49] [50] [51] (Summarized in [28] [29] [30] [31] [32] , pancreatic islet development [33] [34] [35] , beta cell proliferation [36] [37] [38] maintenance of beta cell function [39] [40] [41] , pancreas regeneration, [42, 43] and islet cell death Studies have examined the expression of miRnAs in skeletal muscle from Goto Kakizaki rats [58] [59] [60] , a model of insulin resistance and diabetes [61] . Different miRnAs including miR-222, miR-27a, miR-195, miR-103 are altered in type 2 diabetes. A recent study also suggests a role of miR-106b in mitochondrial dysfunction and insulin resistance of c2c12 myotubes [62] . miR- Skeletal muscle muscle tissue, the primary site of glucose uptake, accounts for approximately 75% of insulin-dependent glucose removal from the plasma [52] . miR-1, miR-133 and miR-206, which are also called as myomiRs due to their muscle-specific expression, regulate muscle proliferation and differentiation [53, 54] .
Gene targets of miR-1 and miR-133a are involved in glucose homeostasis. miR-133 has been shown to alter expression of insulin like growth factor-1 receptor (IGF-R1) in developing skeletal muscle [47] as well as the glucose transporter GLUT4
by inhibiting expression of the Krüppel-like transcription factor KLF15 [55] . miR-1 also targets insulin like growth factor 1 (IGF-1), blocking the capacity of glucose induced IGF-1 to cause mitochondrial dysfunction, cytochrome-c release and apoptosis in cardiomycytes [56] . Both IGF-1 and IGF-R1 were shown to be targets of miR-1 in c2c12 myoblasts; interestingly, this study also determined that IGF-1 is able to regulate the expression of miR-1 via the transcription factor FoxO3a [57] . expression of insulin receptor substrates (IRS). miR-33a/b inhibit the expression of IRS-2 in cultured hepatic cells reducing the activation of insulin signalling pathways including AKT and ERK [74] . IRS-1 has been shown to be down-regulated by miR-126
in the hepatic cancer cell line SK-Hep-1 [75] . miR-145 has also been shown to down-regulate IRS-1 in human colon cancer cells but it is unclear whether this is also the case in the liver [76] .
Recently, the effect of the miR-29 family on the liver of diabetic mice has been explored [77] . Overexpression of these miRnAs, through adenovirus vectors, leads to improved fasting glucose and insulin tolerance in diet-induced obese mice. It is thought that this effect is a direct result of lowering hepatic gluconeogenesis via the decrease of PGc-1α and G6Pase protein levels.
cardiac muscle cardiac muscle, and muscle tissue in general, is a major site of glucose uptake. Therefore, many of the cardiac-specific miRnAs impact upon this process. miR-133, as discussed under the 'skeletal muscle' section (above), is seen to negatively regulate the expression of GLUT4, a major glucose transporter in cardiac muscle [78] . Indeed, when miR-133 is overexpressed in cardiomyocytes it lowers GLUT4 expression and the associated insulin-induced glucose uptake [55] . conversely, miR-223 has been shown to increase the levels of GLUT4 within cardiomyocytes [79] . subset also found to be altered in individuals who had impaired glucose tolerance [64] suggesting that some expression changes occur before the onset of diabetes.
Adipose tissue
In adipose tissue, insulin stimulates lipogenesis, the conversion of blood glucose into fatty acids for efficient energy storage.
microRnAs are demonstrated to be important in adipocyte lineage commitment, differentiation and proliferation. miR-143
has been shown to be involved in adipocyte differentiation both in vivo and in vitro [65, 66] . Overexpression of miR-143 and miR-103 in pre-adipocytes leads to an increase in the expression of adipogenesis markers and triglyceride accumulation.
Interestingly, both miR-143 and miR-103 are downregulated in adipocytes from ob/ob mice which are insulin resistant and obese [66] . miR-143 overexpressing mice demonstrate impaired insulin sensitivity, while miR-143 knock out animals do not develop obesity symptoms [67] . This indicates that miR-143 is one of the regulators of obesity and diabetes.
The miR-29 family (miR-29a, b and c) have been shown to be upregulated in both the skeletal muscle and adipose tissue of diabetic Goto Kakizaki rats [60] . The upregulation of miR29a and miR-29b could be reproduced in vitro when 3T3-L1 adipocytes were incubated in the presence of high glucose and insulin. Indeed, overexpresion of miR-29 in the same cell type decreased insulin-stimulated glucose uptake [60] . These results suggest that miR-29 may be involved in mechanisms leading to insulin resistance in type 2 diabetes.
Liver
Selective deletion of the miRnA processing enzyme Dicer1 in the liver early after birth leads to mild hyperglycemia in the fed state and in severe hypoglycaemia in the fasting state due to a depletion of glycogen storage [68] . The expression levels of 4 microRnAs that are highly enriched in the liver, miR-122, miR-148a, miR-192 and miR-194, were found to be decreased in Dicer null hepatocytes indicating that these miRnAs are important for hepatic glucose homeostasis.
miR-122 is the most abundant miRnA in the liver, with copy numbers reaching 50,000-82,000 per average mouse liver cell, and 135,000 per primary human hepatocyte [69] . In mice, inhibition of miR-122 leads to a decrease in hepatic fatty acid and cholesterol synthesis along with a reduction in plasma cholesterol [70] . Inhibition of miR-122 in a mouse model of dietinduced obesity also led to a reduction of plasma cholesterol.
These results suggest that miR-122 inhibition may be of therapeutic benefit in lowering plasma cholesterol levels. For example, it was demonstrated that miR-208, exclusively expressed in the heart, was measured in serum after cardiac tissue injury [94] . As demonstrated in Figure 2 , a damaged cell will result in release of such tissue-specific microRnA containing vesicles into surrounding space that drains either to vascular / lymphatic systems. Similar mechanism involving the release of cellular contents (including miRnAs) can exist in conditions such as endothelial damage, diabetes and cancer, which involve the death/lysis of specific cell types.
There are a number of criteria that are required for a molecule to be considered as a good biomarker. Overall, microRnAs fulfil most/all of these criteria and can therefore be good biomarkers, if the specificity is identified. for tumor propagation and invasion [85] . A recent study has also indicated that activated macrophages release oncogenic miRnAs in exosomes that increase invasiveness of breast cancer cells [86] . There are other reports indicating a role of exosomal miRnAs in immune response modulation [87, 88] microRnAs are also potential biomarkers for early prediction of diabetic complications. circulating miRnAs in serum as well as in urine are identified in different renal diseases [113] [114] [115] [116] .
In one study, circulating miRnAs (miR-16, miR-21, miR-210, miR-638) were found at lower levels in chronic kidney disease and their expression correlated with glomerular filtration rate [113] . Recently, differentially expressed miRnAs are reported in the urine samples from individuals at various stages of diabetic nephropathy [116] . Though there are no studies reporting circulating miRnAs as biomarkers for other diabetic complications, they are predicted to be important in early diagnosis of the disease pathology [117, 118] . but it is unclear whether these individual microRnAs can prove to be the most reliable measurement for identification of pancreatic beta cell death in humans. most current studies involve few patient samples (<50) and are not sufficiently powered to identify any differences. The exception to this was the Bruneck cohort, which considered over 800 individuals, however, data was only 1. Specificity -the molecule should be specific to a diseased organ or tissue and able to differentiate pathologies.
Additionally, the levels should be proportional to the degree of severity of pathology. There has been extensive research into the miRnA profiles of many different cancer types reviewed in [95] and there are a number of studies suggesting that differential serum miRnA levels are able to determine patient prognosis [96, 97] . Such information is lacking for diabetes.
Once a signature of microRnAs that offers the highest specificity for detection of beta cell death is available, monitoring of an individual's pancreatic health and clinical prognosis would be attainable.
2.
Sensitive -there should be significant release upon the development of pathology in a short time frame. A number of studies have examined the expression of microRnAs in the serum of individuals following myocardial infarction (mI). miR-1 [98] and miR-208 [94] have been shown to be elevated in the hours following mI, returning to baseline levels in the following weeks.
Another study was able to detect miR-208 in 20 patients following mI whilst troponin, the most commonly used biomarker of cardiac damage, was only detected in 17 of these individuals [99] .
3.
Stable -the molecule should be able to be detected in samples which may not have been stored in ideal conditions or have undergone fixation protocols. Serum miRnA has been shown to be resistant to multiple cycles of freeze-thawing as well as high pH [14, 15] . miRnA profiles are also able to be determined in formalin fixed tissue [96, 100, 101 ]. 5. non-invasive -the molecule should be present in easily accessible fluid samples. To date miRnAs have been detected in a number of body fluids including serum and plasma [14] [15] [16] , whole blood [105] , urine [17, 18] , faeces [19, 20] , saliva [21, 22] and breast milk [23] .
In recent years, there have been reports of using miRnAs for prediction / early detection of diabetes using human samples.
Zampetaki [106] and Kong et al [107] were among the first to describe differentially expressed miRnAs in diabetic populations.
A study further correlated an increase of miR-27a and miR-320a
with high blood glucose and associated these miRnAs with T2D [108] . Another very recent study has examined miR-375, an islet-specific miRnA, in streptozotocin-induced diabetic animal models, implicating a release of this miRnA due to beta cell death [109] . nielsen et al described a microRnA signature (group of 12 miRnAs) that is differentially expressed between newly diagnosed T1D and control individuals [110] . They also correlated the expression of miR-25 to residual beta cell function as measured by circulating c-peptide levels. Few studies also analysed miRnAs in immune cells of T1D patients to understand if there are any changes associated with the miRnA profiles and initiation of autoimmune attack [111, 112] . Though these reports that are highly disease specific and should not mislead to other organ damages. As discussed earlier, determining the specificity of miRs towards a particular biology, in this case beta cell death, is important. One approach is to understand the miRnAs that are crucial to development of the endocrine pancreas. Such miRs would be potentially involved in function and maintenance of endocrine pancreatic cells and can therefore be used as potential biomarkers of beta cell death.
An example of this is the recent presentation by Erener, S. et al [111] of miR-375 as a biomarker of beta cell death (in mice).
Using such a signature of multiple miRnAs involved in beta cell development ("cradle") for identification of beta cell death available on a small number who developed diabetes during the course of the study [106] . In order to determine a miRnA profile that is predictive of diabetes, a large number of individuals need to be included in a longitudinal study setting that involves at least 3 time points over several months -years. Another issue that needs to be addressed is the number of miRnA that need to be considered in order to accurately assess an individual's risk of disease. To date, ~ 1 in 3 diabetic individuals were incorrectly assessed on the expression of 5 [106] or 7 [107] miRnA in the serum or plasma, clearly suggesting that the number of miRnA considered needs to be reassessed for their specificity, suitability and stability.
A major drawback in the use of miRnAs as biomarkers is the length of time required for sample processing. In our hands, this process from RnA isolation to data generation takes approximately 8 hours. In most labs, this is labour intensive process but has several potential stages for automation wherein robotics and micro-/ nano-fluidics can be integrated to improve the throughput and sensitivity of the assay. However, significant differences can be introduced between labs that use different chemistries (eg: SybrG Vs Taqman) or platform for detection through discovery analysis would become more easy to achieve.
currently, it is difficult to understand the potentially multiple roles that miRnAs play in circulation as well as their origin in the circulation. It is crucial to select a panel of miRnAs
